Our initial focus is to develop a pain-free drug delivery solution.

Delivering drugs effectively to the deep lung remains a major challenge in modern medicine. Current technologies often rely on large particles or complex delivery systems, which limit how far the drug can travel within the respiratory system. As a result, much of the medication fails to reach the target region, reducing treatment efficiency.

1 in 12 people globally are affected by chronic respiratory diseases

Millions of deaths occur globally each year

Around 3.3+ million Australians have major lung diseases requiring inhaled treatment

  • What is the problem?

    Current inhaler and pulmonary drug delivery systems often struggle to deliver medicine deep into the lungs efficiently.

  • Why is it a problem?

    Large particle size, drug loss in the mouth or upper airway, user technique dependence, and complex devices can reduce treatment effectiveness.

  • Who is affected?

    Patients with respiratory diseases such as asthma, COPD, and other chronic lung conditions

  • Why current technology is not enough

    Many existing systems require advanced devices or still fail to achieve consistent deep lung deposition.

  • Why It Matters

    Better pulmonary drug delivery means:

    more efficient treatment

    deeper lung penetration

    reduced drug wastage

    improved patient outcomes

Our Approach

IonMist is developing a simpler and more effective way to improve pulmonary drug delivery through advanced particle engineering.

Learn More